Prostate cancer treatment can impair fertility through different mechanisms even when the testes themselves are not removed. Radical prostatectomy permanently prevents normal semen ejaculation and therefore prevents natural conception, although testicular sperm production may continue. Prostate radiotherapy can expose the testes to scattered radiation and reduce sperm production temporarily or permanently depending on dose. Androgen deprivation suppresses the hormonal signals needed for testosterone and spermatogenesis, while bilateral orchiectomy permanently removes the sperm-producing organs. Because some of these effects cannot be reversed, fertility preservation should be discussed before treatment whenever future biological parenthood matters.
The most reliable fertility-preservation strategy for a postpubertal man facing prostate cancer treatment is usually sperm cryopreservation before therapy begins. The 2025 ASCO fertility-preservation guideline recommends offering sperm banking before cancer-directed treatment and recommends testicular sperm extraction with cryopreservation when a patient cannot produce an ejaculated sample. After radical prostatectomy, natural conception is no longer possible because normal ejaculation is anatomically eliminated, but the testes can still produce sperm in some men, allowing surgical sperm retrieval for IVF/ICSI in selected survivors. Radiation and hormonal therapy can also damage or suppress spermatogenesis, so treatment-specific counseling should occur before the first operation, radiation fraction or systemic dose.
01How Can Prostate Cancer Treatment Affect Male Fertility?
Fertility requires more than sperm production
For natural conception, several systems must work together:
- the testes must produce viable sperm;
- sperm must move through the epididymis and vas deferens;
- seminal vesicles and prostate normally add fluid to form semen;
- semen must reach the urethra;
- ejaculation must deliver it outside the body;
- and sperm must be capable of fertilizing an egg.
Prostate cancer treatment can interrupt different points in that chain.
How does prostatectomy affect fertility?
Radical prostatectomy usually removes:
- the prostate;
- the seminal vesicles;
- the ejaculatory ducts within the surgical specimen;
- and the connection between the vas deferens and the urethral semen pathway.
The testes remain unless a separate orchiectomy is performed.
This creates a distinctive situation:
sperm production may continue, but sperm no longer have a natural route into an ejaculate.
How does radiation affect fertility?
The testes are not normally inside the prostate radiation target.
However, they can receive scattered radiation from:
- the treatment beams;
- pelvic nodal fields;
- treatment-machine leakage;
- and daily imaging used for setup.
Sperm-producing germ cells are substantially more radiation-sensitive than the testosterone-producing Leydig cells.
Even relatively low testicular doses can therefore reduce sperm count before a major testosterone change becomes apparent.
How does androgen deprivation affect fertility?
Androgen deprivation suppresses the hypothalamic-pituitary-gonadal axis.
Lower LH and testosterone reduce the hormonal environment required for normal spermatogenesis.
During treatment this can cause:
- marked reduction in sperm production;
- testicular volume change;
- loss of libido;
- erectile dysfunction;
- and little or no opportunity for natural conception.
After temporary medical androgen deprivation, reproductive recovery may occur, but it is variable and can be slow after long treatment courses.
What if the testes are surgically removed?
Bilateral orchiectomy permanently removes:
- the main testosterone-producing tissue;
- and the organs that produce sperm.
After both testes are removed, future sperm retrieval is not possible. Biological parenthood using the patient’s own sperm therefore depends on material stored before surgery.
Are orgasm, ejaculation and fertility the same?
No.
The previous page, Sex and Ejaculation After Prostate Cancer Treatment, explains why orgasm can remain after prostatectomy despite permanent loss of semen ejaculation.
Fertility asks a different question:
Is viable sperm available for biological parenthood, either naturally or through assisted reproduction?
Fertility loss after prostate treatment is not always the same as testicular failure. After prostatectomy, the testes may still make sperm even though natural ejaculation is impossible. That distinction is what makes surgical sperm retrieval biologically possible in selected survivors.
02Can a Man Have Biological Children After Radical Prostatectomy?
Natural conception is no longer possible through intercourse after standard radical prostatectomy
The operation permanently removes the normal semen pathway.
After surgery:
- there is no normal antegrade ejaculation;
- the prostate and seminal vesicles no longer produce seminal fluid;
- and sperm produced in the testes no longer reach the urethra through the usual reproductive tract.
This is why fertility preservation must ideally be discussed before surgery rather than after the patient discovers that orgasm is dry.
Does radical prostatectomy stop sperm production?
Not necessarily.
The testes are left in place during prostatectomy.
If testicular function is intact:
- spermatogenesis may continue;
- but sperm are inaccessible through a normal semen sample.
Can sperm be retrieved after prostatectomy?
Yes, in selected patients.
Surgical sperm retrieval can obtain sperm directly from testicular tissue.
Techniques include:
- testicular sperm extraction (TESE);
- and microdissection TESE in selected situations.
Retrieved sperm generally require assisted reproduction, usually IVF with intracytoplasmic sperm injection (ICSI), because only small numbers of sperm may be available and there is no natural ejaculate.
Is post-prostatectomy sperm retrieval guaranteed?
No.
The probability depends on whether sperm production survived:
- age-related reproductive decline;
- prior infertility;
- radiation;
- androgen deprivation;
- chemotherapy if it was used;
- or other testicular injury.
Evidence specific to sperm retrieval after prostate-cancer treatment remains much smaller than the general male-infertility literature.
Why is sperm banking before prostatectomy preferable?
Before surgery:
- an ejaculated sample can usually be collected without an invasive procedure;
- multiple samples may be stored;
- and reproductive specialists have more flexibility regarding future insemination or IVF/ICSI.
After surgery, access to sperm usually requires a procedure.
How often is fertility counseling missed?
A 2025 study surveyed 364 men aged 50 or younger shortly after radical prostatectomy.
It found:
- 28% were interested in future fertility;
- 58% did not recall being told about post-prostatectomy anejaculation;
- 84% were unaware sperm banking before surgery was an option;
- only 7% of men interested in fertility actually banked sperm;
- and only 2% knew testicular sperm extraction could be an option after surgery.
This was a single survey population rather than a national prevalence study, but it highlights the practical cost of discussing fertility too late.
Does nerve-sparing surgery preserve fertility?
No.
Nerve sparing aims to improve the probability of erectile recovery.
It does not preserve:
- the prostate;
- seminal vesicles;
- or a normal ejaculatory route.
A perfectly successful bilateral nerve-sparing prostatectomy can therefore preserve erections while still causing permanent natural infertility.
Nerve preservation and fertility preservation solve different problems. Nerve sparing addresses erectile signaling; sperm banking preserves reproductive material. One should never be presented as a substitute for the other.
03How Do Radiation and Hormone Therapy Affect Sperm and Fertility?
Prostate radiation does not need to directly target the testes to affect sperm production
Spermatogonia—the stem cells that produce sperm—are highly radiosensitive.
The testes can therefore be affected by scattered radiation even though they sit outside the prostate target.
What do modern prostate-radiotherapy plans show?
A 2024 retrospective analysis reviewed 100 contemporary prostate-radiotherapy plans.
The median estimated testicular dose was:
- 0.58 Gy overall;
- 0.18 Gy with stereotactic plans;
- 0.62 Gy with VMAT;
- 1.50 Gy with tomotherapy.
Pelvic nodal radiation increased the median testicular dose to:
- 1.18 Gy with nodal treatment;
- versus 0.26 Gy without nodal treatment.
Did that study measure actual infertility?
No.
This is an important limitation.
It was a dosimetry study, not a prospective fertility-outcome trial.
Using established theoretical dose thresholds, the authors estimated:
- 65% of patients crossed a dose associated with transient azoospermia;
- and 10% received more than 2 Gy, a dose the authors considered likely to cause permanent azoospermia.
Those values demonstrate biological plausibility and planning concern—not a measured 65% infertility rate.
Can sperm production recover after radiation?
Sometimes.
Recovery depends on:
- testicular dose;
- fractionation;
- age;
- baseline sperm production;
- and whether enough spermatogonial stem cells survive.
A broader 2024 review of radiation and testicular function concluded that even relatively low direct or scattered doses can reduce sperm count and quality, while Leydig cells that produce testosterone are generally more radiation resistant.
Does brachytherapy eliminate fertility risk?
No.
Historically, brachytherapy often exposes the testes to less scatter than broad external-beam fields, but:
- the prostate remains irradiated;
- ejaculate volume and ejaculation can change;
- and fertility outcomes are much less studied than cancer-control outcomes.
A patient who wishes to preserve biological parenthood should not choose brachytherapy under the assumption that fertility is guaranteed.
What does androgen deprivation do to sperm production?
Medical androgen deprivation suppresses:
- LH;
- testicular testosterone;
- intratesticular androgen signaling;
- and spermatogenesis.
Recovery after temporary treatment is possible but can be delayed.
Longer hormonal suppression and older age generally make recovery less predictable.
Can hormone suppression be used to protect sperm during cancer treatment?
No.
The 2025 ASCO fertility-preservation guideline specifically states that hormonal suppression should not be offered to males as a fertility-preservation strategy because it is not effective as gonadal protection.
What is different about orchiectomy?
Medical androgen deprivation may be reversible.
Bilateral orchiectomy is not.
Once both testes are removed:
- new sperm cannot be produced;
- surgical sperm retrieval is no longer possible;
- and future use of the patient’s sperm depends on pre-treatment cryopreservation.
Do not translate radiation dose thresholds directly into personal pregnancy odds. Modern planning studies establish testicular exposure and biological risk, but actual post-treatment fatherhood depends on baseline fertility, sperm recovery, partner factors and use of assisted reproduction.
04How Can Fertility Be Preserved Before Prostate Cancer Treatment?
Ask the fertility question before choosing an irreversible treatment
ASCO’s 2025 guideline recommends fertility-risk counseling:
- at cancer diagnosis;
- before cancer-directed therapy;
- and again during survivorship when reproductive goals change.
Patients who:
- want future biological children;
- are uncertain;
- or simply want to preserve the option;
should be offered timely referral to reproductive specialists.
What is the standard male fertility-preservation method?
Sperm cryopreservation—sperm banking.
ASCO considers ejaculated sperm cryopreservation an established method and recommends offering it before cancer-directed treatment.
How many sperm samples should be banked?
More samples provide more future reproductive flexibility.
The 2025 ASCO update notes that fertility clinicians commonly aim for multiple ejaculates and empirically may prefer approximately three samples of adequate quality.
But the guideline emphasizes flexibility:
- cancer treatment should not be unnecessarily delayed;
- collect as many samples as reasonably possible;
- and do not abandon preservation simply because only one sample can be obtained.
With ICSI, even a small number of cryopreserved sperm can remain clinically useful.
What if the patient cannot produce a semen sample?
The 2025 ASCO guideline recommends offering:
testicular sperm extraction with sperm cryopreservation
to pubertal/postpubertal males who cannot produce a semen sample before cancer treatment.
Should fertility preservation happen before the first treatment?
Whenever possible, yes.
ASCO specifically warns that sperm collected after cancer-directed therapy has begun can have:
- worse quality;
- and potentially greater genetic/DNA damage.
This is why banking before treatment is preferred.
What if treatment already started?
The situation becomes individualized.
ASCO allows post-treatment fertility-preservation assessment, but timing should be determined with reproductive specialists because:
- sperm quality may be temporarily impaired;
- spermatogenesis may recover over time;
- and the appropriate interval varies by treatment.
There is no single prostate-cancer-wide waiting period that fits surgery, radiation and every systemic regimen.
Should a patient bank sperm before active surveillance?
Active surveillance itself does not remove the reproductive tract or irradiate the testes.
Immediate banking is therefore not mandatory simply because prostate cancer exists.
However, fertility planning can still be reasonable when:
- future definitive treatment is likely;
- age-related fertility decline is a concern;
- semen quality is already borderline;
- or future reproductive flexibility is important.
Can fertility preservation change the cancer treatment choice?
Fertility can be one preference in shared decision-making, but it should not override oncological safety.
A patient should not accept inadequate cancer treatment solely to preserve natural ejaculation.
The practical strategy is usually:
preserve reproductive material first, then choose the cancer treatment appropriate for the disease.
| Situation | Fertility issue | Preservation / reproductive direction |
|---|---|---|
| Before radical prostatectomy | Natural ejaculation will be permanently lost. | Offer sperm cryopreservation before surgery. |
| Before prostate radiation | Scatter can impair sperm production/quality; recovery is uncertain. | Offer sperm banking before first fraction when future fertility matters. |
| Before long-course ADT | Spermatogenesis and sexual activity will be suppressed; recovery may be delayed. | Bank sperm before systemic suppression where feasible. |
| Unable to ejaculate before treatment | No semen sample available. | ASCO recommends offering TESE with cryopreservation. |
| After prostatectomy, no sperm banked | No normal ejaculate but testes may still produce sperm. | Reproductive-urology evaluation for surgical sperm retrieval + IVF/ICSI. |
| After radiation | Spermatogenesis may be reduced or recover variably. | Specialist-directed timing, semen assessment and ART planning. |
| After bilateral orchiectomy | No remaining sperm-producing tissue. | Own-sperm biological parenthood requires sperm preserved before surgery. |
The most important fertility intervention is often timing. A short pre-treatment discussion can preserve options that become technically difficult—or impossible—after prostatectomy, radiation, long hormonal treatment or orchiectomy.
05Where Does This Prostate-Cancer Fertility Page End?
This page owns the cancer-treatment relationship
The prostate-cancer-specific questions answered here are:
- why radical prostatectomy prevents natural conception;
- why sperm production may continue after surgery;
- how prostate radiotherapy can expose the testes;
- how androgen deprivation suppresses spermatogenesis;
- when sperm banking should occur;
- and when post-treatment sperm retrieval may still be possible.
What belongs in the future Male Fertility root?
The planned Male Fertility root should own the broader reproductive evaluation, including:
- semen analysis interpretation;
- azoospermia and oligospermia;
- FSH, LH and testosterone evaluation;
- varicocele;
- genetic testing;
- general TESE/microTESE selection;
- IUI, IVF and ICSI selection;
- partner-factor evaluation;
- and infertility unrelated to prostate cancer treatment.
Because that root is marked as future content in the current architecture, this publication-ready version does not create a live internal link that could produce a 404. Once the Male Fertility root is published, the phrase Male Fertility in this section should become the descriptive bridge anchor.
What is the next prostate-cancer survivorship topic?
The next contextual page is Libido After Prostate Cancer Treatment.
That page should own:
- sexual desire;
- androgen-deprivation-related libido loss;
- distinguishing low desire from erectile dysfunction;
- and recovery after temporary hormonal therapy.
Why separate libido from fertility?
A man can have:
- no libido but preserved sperm production;
- normal sexual desire but permanent infertility after prostatectomy;
- or impaired spermatogenesis after radiation despite adequate erections.
These are different biological outcomes and deserve different canonical pages.
When should reproductive-specialist referral be prioritized?
Referral is particularly important when:
- future biological parenthood is important or uncertain;
- definitive treatment is imminent;
- the patient cannot provide an ejaculated sperm sample;
- prior infertility is known;
- radiation or long-term hormonal treatment has already occurred;
- or post-prostatectomy sperm retrieval is being considered.
Bridge rule: explain the prostate-cancer-treatment → fertility relationship here, then hand off the full semen-analysis, azoospermia, endocrine, genetic and assisted-reproduction framework to the future Male Fertility root once it exists.
→Fertility Effects by Prostate Cancer Treatment
| Treatment | What happens to sperm production? | What happens to natural conception? | Preservation priority |
|---|---|---|---|
| Active surveillance | No direct treatment-related gonadal injury. | Generally preserved while untreated. | Individualize based on age, baseline fertility and probability of later definitive treatment. |
| Radical prostatectomy | May continue because testes remain. | Natural conception becomes impossible because normal ejaculation route is permanently lost. | Bank sperm before surgery. |
| External-beam radiation | Can decline from incidental testicular radiation; recovery varies with dose. | May remain possible initially but semen/ejaculation and sperm quality can deteriorate. | Bank before radiation if future biological parenthood matters. |
| Brachytherapy | Likely lower testicular scatter than many broad external fields, but fertility is not guaranteed. | May remain possible, while ejaculate volume/function can decline. | Discuss banking rather than assuming reproductive preservation. |
| Temporary medical ADT | Strongly suppressed during therapy; recovery may occur after stopping. | Often functionally absent during treatment because sperm production, libido and erections fall. | Bank before prolonged treatment when relevant. |
| Bilateral orchiectomy | Permanently eliminated. | Impossible using newly produced own sperm. | Cryopreserve sperm before surgery if biological parenthood is desired. |
Key Points
- Fertility after prostate cancer treatment depends on sperm production, sperm transport, ejaculation and the treatment’s gonadal effects.
- Radical prostatectomy permanently prevents natural conception through intercourse because normal semen ejaculation is eliminated.
- The testes remain after prostatectomy, so sperm production may continue even though sperm cannot enter a natural ejaculate.
- Selected post-prostatectomy survivors may undergo testicular sperm retrieval for IVF/ICSI when viable sperm remain.
- Nerve-sparing prostatectomy does not preserve the normal ejaculatory pathway and is not a fertility-preservation strategy.
- A 2025 survey of younger radical-prostatectomy patients found 28% expressed future fertility interest, yet 84% were unaware preoperative sperm banking was an option.
- Prostate radiation can expose the testes to scattered radiation despite the testes being outside the target.
- A 2024 analysis of 100 modern prostate-radiotherapy plans found a median estimated testicular dose of 0.58 Gy.
- Pelvic nodal irradiation increased median testicular dose to 1.18 Gy versus 0.26 Gy without nodal treatment in that study.
- The study estimated theoretical azoospermia risk from dosimetry; it did not measure a 65% clinical infertility rate.
- Sperm-forming germ cells are more radiation sensitive than testosterone-producing Leydig cells.
- Medical androgen deprivation suppresses spermatogenesis during treatment, and recovery after stopping can be delayed or incomplete.
- Hormonal suppression should not be used as a male fertility-preservation technique; ASCO states it is ineffective for gonadal protection.
- Bilateral orchiectomy permanently removes sperm production, so future own-sperm parenthood depends on material preserved beforehand.
- ASCO’s 2025 fertility-preservation guideline recommends offering sperm cryopreservation to pubertal/postpubertal males before cancer-directed therapy.
- If an ejaculated sample cannot be produced before treatment, ASCO recommends offering testicular sperm extraction with cryopreservation.
- More stored sperm samples provide greater reproductive flexibility, but even one collection can be worth preserving when treatment timing is tight.
- Sperm should preferably be collected before cancer-directed treatment because therapy can affect sperm quality and DNA integrity.
- There is no single post-treatment waiting period for attempting conception that applies to every prostate-cancer therapy.
- The future Male Fertility root should own general semen analysis, azoospermia, endocrine/genetic work-up and complete ART decision-making.
Clinical bottom line: fertility should be discussed before prostate cancer treatment whenever future biological parenthood matters—or when the patient is unsure. Radical prostatectomy causes permanent anatomical infertility through loss of the normal semen pathway even though sperm production may continue in the testes. Radiation can expose highly radiosensitive sperm-producing cells to scattered dose, while androgen deprivation suppresses the hormonal environment required for spermatogenesis. Bilateral orchiectomy permanently removes the sperm-producing organs. Because post-treatment recovery is uncertain and sperm retrieval after surgery is more invasive than providing a semen sample beforehand, sperm cryopreservation before treatment is the most dependable established preservation strategy for many postpubertal men. If a semen sample cannot be produced, current ASCO guidance supports pre-treatment testicular sperm extraction with cryopreservation. The broader male-infertility work-up belongs in the future Male Fertility root; this page stays focused on the prostate-cancer-treatment relationship.
Medical disclaimer: This article provides general medical education about fertility specifically in relation to prostate cancer treatment. Fertility risk and preservation options depend on age, baseline semen quality, prior fertility, prostate cancer treatment, radiation field and dose, systemic therapy, partner factors and reproductive goals. Patients interested in future biological parenthood should discuss fertility preservation with their oncology/urology team and a reproductive urologist or fertility specialist before cancer-directed treatment whenever possible.
For the broader disease framework, return to the Prostate Cancer hub. The previous survivorship page covers Sex and Ejaculation After Prostate Cancer Treatment. The next contextual page covers Libido After Prostate Cancer Treatment. The broader Male Fertility hub is marked as future content in the current FBU architecture and should become the descriptive bridge target once published.
Evidence Sources
- ASCO 2025 Guideline Update — Fertility Preservation in People With Cancer: pre-treatment sperm cryopreservation, pre-treatment TESE when an ejaculated sample cannot be produced, post-treatment counseling and timing principles.
- ASCO Clinical Insights, published in JCO Oncology Practice 2026 — implementation of current fertility-preservation guidance and post-treatment reproductive counseling.
- AUA/ASRM — Diagnosis and Treatment of Infertility in Men: counseling before gonadotoxic cancer therapy and fertility-preservation principles.
- National Cancer Institute — Male Fertility and Cancer: surgery, radiation and systemic treatment effects on fertility.
- Radiation Oncology 2024 — testicular dose from 100 modern prostate-radiotherapy plans, including SBRT, VMAT, tomotherapy and pelvic nodal irradiation.
- 2024 comprehensive review — radiation effects on spermatogenesis and testicular endocrine function.
- 2025 radical-prostatectomy fertility survey — patient interest in future fertility, counseling gaps, sperm-banking awareness and knowledge of post-treatment sperm extraction.
- 2025 review — prostate cancer treatments and male fertility, including post-prostatectomy anatomical infertility, persistence of testicular sperm production and surgical sperm-retrieval options.